<SEC-DOCUMENT>0001140361-19-022636.txt : 20191216
<SEC-HEADER>0001140361-19-022636.hdr.sgml : 20191216
<ACCEPTANCE-DATETIME>20191216171201
ACCESSION NUMBER:		0001140361-19-022636
CONFORMED SUBMISSION TYPE:	SC 13D
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20191216
DATE AS OF CHANGE:		20191216
GROUP MEMBERS:		ARGON MERGER SUB, INC
GROUP MEMBERS:		MERCK SHARP & DOHME CORP.

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARQULE INC
		CENTRAL INDEX KEY:			0001019695
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043221586
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-48819
		FILM NUMBER:		191288018

	BUSINESS ADDRESS:	
		STREET 1:		ONE WALL STREET
		STREET 2:		FLOOR 6
		CITY:			BURLINGTON
		STATE:			MA
		ZIP:			01803
		BUSINESS PHONE:		781-994-0300

	MAIL ADDRESS:	
		STREET 1:		ONE WALL STREET
		STREET 2:		FLOOR 6
		CITY:			BURLINGTON
		STATE:			MA
		ZIP:			01803

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merck & Co., Inc.
		CENTRAL INDEX KEY:			0000310158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221918501
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D

	BUSINESS ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033
		BUSINESS PHONE:		908-740-4000

	MAIL ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merck & Co. Inc.
		DATE OF NAME CHANGE:	20091103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SCHERING PLOUGH CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D
<SEQUENCE>1
<FILENAME>nc10006926x1_sc13d.htm
<DESCRIPTION>SC 13D
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 6.5.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;" align="center"><font style="font-size: 14pt;">UNITED STATES</font></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">SCHEDULE 13D</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">ArQule, Inc.</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(Name of Subject Company &#8212; Issuer)</div>
    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Common Stock, par value $0.01 per share</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(Title of Class of Securities)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">04269E107</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(CUSIP Number of Class of Securities)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Geralyn S. Ritter</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Senior Vice President and Corporate Secretary</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Merck &amp; Co., Inc.</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">2000 Galloping Hill Road Kenilworth, NJ 07033</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(908) 740-4000</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">Copies to:</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Catherine J. Dargan, Esq.</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Michael J. Riella, Esq.</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Covington &amp; Burling LLP</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">One CityCenter</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">850 Tenth Street, NW</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Washington, DC 20001-4956</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">+1 (202) 662 6000</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">December 6, 2019</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(Date of Event Which Requires Filing of this Statement)</div>
    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div style="font-family: 'Times New Roman', Times, serif;">If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because Sec. 240.13d-1(e),
      240.13d-1(f) or 240.13d-1(g) check the following box. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;">Note:</font> Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Sec. 240.13d-7(b) for
      other parties to whom copies are to be sent.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">* The remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
      containing information which would alter disclosures provided in a prior cover page.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The information required on the remainder of this cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Act&#8221;) or otherwise
      subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">CUSIP No. 04269E107</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7a503a97638f4d948ba3d3e2375d9a7c" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Names of Reporting Persons</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">MERCK &amp; CO., INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">2</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Check the Appropriate Box if a Member of a Group: (a) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> (b) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">3</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">SEC Use Only</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">4</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Source of Funds</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">OO (See Item 3)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">5</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Check Box if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Citizenship Or Place Of Organization</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">NEW JERSEY</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" rowspan="4" style="vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); text-align: center;">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif;">NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON&#160; WITH:</div>
          </td>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Sole Voting Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">8</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Shared Voting Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">17,481,903*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">9</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Sole Dispositive Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Shared Dispositive Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">17,481,903*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">11</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Aggregate Amount Beneficially Owned By Each Reporting Person</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">17,481,903* (See Items 4 and 5)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">12</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Check if the Aggregate Amount in Row (11) Excludes Certain Shares: <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">13</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Percent Of Class Represented By Amount In Row (11)</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">12.6%*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">14</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Type Of Reporting Person</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">CO/HC</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">* Beneficial ownership of the common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), of ArQule, Inc. (the &#8220;Issuer&#8221;) is being reported hereunder solely because the Reporting Persons (as
      defined below) may be deemed to have beneficial ownership of such Common Stock by virtue of the Support Agreements described in Item 4 below. Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission
      by the Reporting Persons that they are the beneficial owners of any Common Stock for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership thereof is expressly
      disclaimed.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The shares of Common Stock over which the Reporting Persons may be deemed to have beneficial ownership are comprised of 17,481,903 shares of Common Stock (including Shares issuable upon
      exercise of outstanding options and warrants to purchase Shares) beneficially owned by the stockholders (the &#8220;Stockholders&#8221;) party to the Support Agreements (as defined below). Generally, upon the exercise of any security convertible or exchangeable
      for any Common Stock by the Stockholders, such shares of Common Stock acquired upon exercise thereof shall be included under the Support Agreements and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of
      Common Stock, if any.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The percentage calculation is based on: (a) 120,787,771 shares of Common Stock outstanding, plus (b) 12,555,012 shares of Common Stock subject to stock options, plus (c) warrants to purchase
      5,361,556 shares of Common Stock, each as of the close of business on December 5, 2019 and based on the representation of ArQule in the Merger Agreement (as defined below).</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">CUSIP No. 04269E107</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0851aa6eca7449c2bb4b1dc81b59468f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Names of Reporting Persons</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">MERCK SHARP &amp; DOHME CORP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">2</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Check the Appropriate Box if a Member of a Group: (a) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> (b) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">3</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">SEC Use Only</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">4</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Source of Funds</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">OO (See Item 3)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">5</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Check Box if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Citizenship Or Place Of Organization</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">NEW JERSEY</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" rowspan="4" style="vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); text-align: center;">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif;">NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON&#160; WITH:</div>
          </td>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Sole Voting Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">8</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Shared Voting Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">17,481,903*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">9</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Sole Dispositive Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Shared Dispositive Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">17,481,903*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">11</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Aggregate Amount Beneficially Owned By Each Reporting Person</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">17,481,903* (See Items 4 and 5)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">12</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Check if the Aggregate Amount in Row (11) Excludes Certain Shares: <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">13</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Percent Of Class Represented By Amount In Row (11)</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">12.6%*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">14</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Type Of Reporting Person</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">CO/HC</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">* See note above with respect to Merck &amp; Co., Inc.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">CUSIP No. 04269E107</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0d829a42fb7142b78ab7453686408cf4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Names of Reporting Persons</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">ARGON MERGER SUB, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">2</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Check the Appropriate Box if a Member of a Group: (a) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> (b) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">3</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">SEC Use Only</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">4</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Source of Funds</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">OO (See Item 3)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">5</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Check Box if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Citizenship Or Place Of Organization</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">DELAWARE</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" rowspan="4" style="vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); text-align: center;">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman',Times,serif;">NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON&#160; WITH:</div>
          </td>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Sole Voting Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">8</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Shared Voting Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">17,481,903*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">9</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Sole Dispositive Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
          <td style="width: 82%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Shared Dispositive Power</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">17,481,903*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">11</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Aggregate Amount Beneficially Owned By Each Reporting Person</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">17,481,903* (See Items 4 and 5)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">12</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Check if the Aggregate Amount in Row (11) Excludes Certain Shares: <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">13</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Percent Of Class Represented By Amount In Row (11)</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">12.6%*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">14</div>
          </td>
          <td colspan="3" style="vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">Type Of Reporting Person</div>
            <div style="margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif;">CO</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">* See note above with respect to Merck &amp; Co., Inc.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 1. Security and Issuer</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">This statement on Schedule 13D (this &#8220;Schedule 13D&#8221;) relates to the common stock, par value $0.01 (the &#8220;Common Stock&#8221; or &#8220;Shares&#8221;), of ArQule, Inc. (&#8220;ArQule&#8221;). The address of the principal
      executive offices of ArQule is One Wall Street, Burlington, Massachusetts 01803.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 2. Identity and Background</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">This Schedule is being filed pursuant to Rule 13d-1 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), by Merck &amp; Co., Inc., a New Jersey corporation (&#8220;Merck&#8221;),
      Merck Sharp &amp; Dohme Corp., a New Jersey corporation (&#8220;Parent&#8221;) and Argon Merger Sub, Inc., a Delaware corporation (&#8220;Purchaser&#8221;, and together with Merck and Parent, the &#8220;Reporting Persons&#8221;). A Joint Filing Agreement among the Reporting Persons is
      attached as Exhibit 3 hereto.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The address of the principal business and the principal office of Merck is 2000 Galloping Hill Road, Kenilworth, NJ, 07033. The address of the principal business and the principal office of
      Parent and Purchaser is One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Parent is a wholly owned subsidiary of Merck, which is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies
      and animal health products. Merger Sub is a wholly owned subsidiary of Parent and has not conducted any business and has no assets, liabilities or obligations of any nature other than those incident to its formation and pursuant to the Merger
      Agreement (as defined below) and the transactions contemplated thereby.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person)
      of the Reporting Persons is set forth on Schedule A.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">During the last five years, none of the Reporting Persons or, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A have been convicted in a criminal proceeding
      (excluding traffic violations or similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order
      enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 3. Source and Amount of Funds or Other Consideration</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The total amount of funds required by the Reporting Persons to purchase all of the outstanding Shares in the Offer (as defined below) and the Merger (as defined below) is approximately $2.7
      billion, plus related fees and expenses. The Reporting Persons currently have available to them in cash on hand all funds necessary for these payments.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 4. Purpose of Transaction</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">On December 6, 2019, Parent and Merger Sub entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with ArQule.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub will commence a tender offer (the &#8220;Offer&#8221;) to purchase all of the outstanding Shares at a
      price of $20.00 per Share (the &#8220;Offer Price&#8221;) in cash, net to the seller in cash, without interest and less any applicable tax withholding.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The obligation of Merger Sub to purchase Shares tendered in the Offer is subject to the satisfaction or waiver of a number of conditions set forth in Annex I to the Merger Agreement, including
      (i) that there shall have been validly tendered and not validly withdrawn Shares (excluding any shares of Company Common Stock tendered pursuant to guaranteed delivery procedures that have not yet been received, as defined by Section 251(h)(6) of the
      DGCL) that, considered together with all other Shares, if any, beneficially owned by Merck and its affiliated entities, represent at least one more Share than half of the sum of (A) all Shares then outstanding as of the expiration of the Offer, and
      (B) all Shares that ArQule is required to issue upon the vesting (including vesting solely as a result of the consummation of the Offer), conversion, settlement or exercise of all then outstanding warrants, options, benefit plans, obligations or
      securities convertible or exchangeable into Shares, or other rights to acquire or be issued Shares regardless of the conversion or exercise price or other terms and conditions thereof; (ii) the expiration or termination of the waiting period under
      the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#8220;HSR Act&#8221;) and receipt of clearance, approval or consent under any other applicable antitrust law; and (iii) those other conditions set forth in Annex I to the Merger
      Agreement.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Following the consummation of the Offer and subject to the terms and conditions of the Merger Agreement, Merger Sub will merge with and into ArQule pursuant to the provisions of the Delaware
      General Corporation Law (the &#8220;DGCL&#8221;) as provided in the Merger Agreement, with ArQule being the surviving corporation (the &#8220;Merger&#8221;). At the effective time of the Merger (the &#8220;Effective Time&#8221;), each Share (other than (i) Shares held in ArQule&#8217;s
      treasury or owned by Parent or Merger Sub or any of their respective direct or indirect wholly-owned subsidiaries and (ii) Shares held by stockholders who have properly demanded appraisal of such Shares in accordance with the DGCL) will be cancelled
      and converted into the right to receive an amount in cash equal to the Offer Price, without interest and subject to any applicable withholding of taxes. Immediately prior to the Effective Time, all outstanding ArQule stock options will, to the extent
      unvested, become fully vested, and at the Effective Time, each ArQule stock option will be cancelled and converted into the right to receive an amount in cash equal to the difference between the Offer Price and the applicable per share exercise
      price, less any applicable tax withholding.&#160; Immediately prior to the Effective Time, all warrants to purchase Shares issued to Oxford Finance LLC on January 6, 2017 or February 16, 2018 that have not been exercised will terminate in accordance with
      their terms.&#160; Following the Effective Time, holders who elect to exercise warrants to purchase Shares issued on October 11, 2017 or November 7, 2017 will be entitled to receive an amount in respect of each Share for which such warrant is exercisable
      immediately prior to the Effective Time equal to (i) the Offer Price minus (ii) the applicable exercise price per share of such warrant, less any applicable withholding tax.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The Merger will be governed by Section 251(h) of the DGCL and will be effected by Merger Sub and ArQule without a stockholder vote pursuant to the DGCL as soon as practicable following the
      consummation of the Offer. The closing of the Merger is subject to customary closing conditions.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Concurrently with the execution and delivery of the Merger Agreement, certain stockholders (the &#8220;Stockholders&#8221;) entered into support agreements (the &#8220;Support Agreements&#8221;) with Parent and Merger
      Sub with respect to 17,481,903 shares owned by the Stockholders (the &#8220;Subject Shares&#8221;). The Subject Shares comprise approximately 12.6% of all outstanding Shares, including shares subject to outstanding options and warrants. Each Stockholder agreed,
      among other things, to tender his, her or its Subject Shares pursuant to the Offer and, if necessary, vote his, her or its Subject Shares (i)&#160; against any Acquisition Proposal (as defined in the Merger Agreement); (ii) against any merger agreement or
      merger (other than the Merger Agreement and the Merger), consolidation, combination, sale of substantial assets, share exchange, reorganization, recapitalization, dissolution, liquidation or winding up of or by the ArQule; and (iii) against any
      proposal, action or agreement that would reasonably be expected to (1) prevent or nullify any provision of the Agreement, (2) result in any of the conditions of the Offer set forth in Annex I of the Merger Agreement or the conditions to the Merger
      set forth in Article 8 of the Merger Agreement not being satisfied or (3) impede, interfere with or prevent the consummation of the Offer or the Merger. No Stockholder may propose, commit or agree to take any action inconsistent with any of the
      foregoing clauses (i), (ii) or (iii).</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Each Stockholder also agreed to not, except as provided in the Support Agreements, (i) offer to transfer, transfer or consent to transfer any of its Subject Shares; (ii) enter into any
      agreement to tender Subject Shares; (iii) grant any proxy, power-of-attorney or other authorization in respect of the Subject Shares; or (iv) deposit any of the Subject Shares into a voting trust or enter into a voting agreement or arrangement. The
      Support Agreements will terminate in certain circumstances, including upon termination of the Merger Agreement. Shared voting and dispositive power with respect to the Subject Shares may be deemed to have been acquired through execution of the
      Support Agreements. The Reporting Persons have not expended any funds in connection with the execution of the Support Agreements.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Parent and ArQule entered into an amended and restated mutual confidential disclosure agreement, effective as of November 25, 2019 (the &#8220;Non-Disclosure Agreement&#8221;), in connection with a
      potential negotiated acquisition transaction that resulted in the Offer.&#160; Pursuant to the Non-Disclosure Agreement, subject to certain customary exceptions, each party agreed to keep confidential certain non-public information disclosed to one party
      or its representatives by or on behalf of the other party and, in the case of Parent, by or on behalf of Parent&#8217;s affiliates, including all analyses or other materials containing such non-public information.&#160; The Non-Disclosure Agreement also
      includes a standstill provision.&#160; Pursuant to this provision, Parent agreed that, among other things and for a period of one year from the date of the Non-Disclosure Agreement, unless specifically invited by the board of directors of ArQule, neither
      Parent nor its affiliates or representatives will (a) effect or propose, or knowingly facilitate or encourage any other person to effect or propose or announce any intention to effect: (i) the acquisition of any voting securities, or rights to
      acquire voting securities, of ArQule; (ii) any merger, consolidation, or business combination with ArQule; (iii) any recapitalization, restructuring, liquidation, dissolution or other similar extraordinary transaction with respect to ArQule; or (iv)
      any &#8220;solicitation&#8221; of &#8220;proxies&#8221; (as such terms are used in Regulation 14A of the Exchange Act) or consents to vote with respect to any voting securities of ArQule, or the initiation, proposal, encouragement or solicitation of stockholders of ArQule
      for the approval of any stockholder proposals with respect to ArQule, or the solicitation, advisement or influence of any person with respect to the voting of any voting securities of ArQule; (b) form, join or in any way participate in a &#8220;group&#8221; (as
      defined in the Exchange Act) with respect to any voting securities of ArQule or otherwise in connection with any of the foregoing; (c) (i) call or seek to call any meeting of stockholders of ArQule, including by written consent, or provide to any
      third party a proxy, consent or requisition to call any meeting of stockholders of ArQule; (ii) seek representation on the board of directors of ArQule; or (iii) seek the removal of any member of the board of directors of ArQule or management of
      ArQule; or (d) publicly disclose any intention, plan or arrangement, whether written or oral, inconsistent with the foregoing.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The purpose of the Offer is to acquire control of, and ultimately following the Merger, the entire equity interest in, ArQule while allowing ArQule&#8217;s stockholders an opportunity to receive the
      Offer Price promptly by tendering their Shares into the Offer. After the consummation of the Offer, Parent and Merger Sub intend to consummate the Merger as promptly as practicable, subject to the satisfaction or waiver of certain conditions. At the
      effective time of the Merger, (i) the certificate of incorporation of the surviving corporation will be amended and restated in its entirety as set forth in an exhibit to the Merger Agreement, (ii) the bylaws of Merger Sub, as in effect immediately
      prior to the effective time of the Merger, will be the bylaws of the surviving corporation, except that the references to Merger Sub&#8217;s name will be replaced with references to the surviving corporation&#8217;s name, and (iii) the directors and officers of
      Merger Sub immediately prior to the effective time of the Merger will be the initial directors and officers of the surviving corporation. Following the Merger, the Shares will no longer be traded on the NASDAQ Global Market, there will be no public
      market for the Shares, and registration of the Shares under the Exchange Act will be terminated. Except as set forth in this Schedule 13D and in connection with the Offer, the Merger and the Support Agreements described above, the Reporting Persons
      do not have any plan or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The foregoing description of (i) the Merger Agreement and the transactions contemplated thereby, (ii) the Support Agreements and the transactions contemplated thereby and (iii) the
      Non-Disclosure Agreement and the transactions contemplated thereby, in each case, do not purport to be complete and are qualified in their entirety by reference to the Merger Agreement, which is filed as Exhibit 2.1 hereto and which is incorporated
      herein by reference, to the Form of Support Agreement, which is filed as Exhibit 99.1 hereto and which is incorporated herein by reference and to the Non-Disclosure Agreement, which is filed as Exhibit 99.2 hereto and which is incorporated herein by
      reference.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The foregoing is neither an offer to purchase nor a solicitation of an offer to sell any Shares or any other securities. A tender offer statement on Schedule TO, including an offer to purchase,
      a letter of transmittal and related documents, will be filed by Parent and Merger Sub with the SEC, and a solicitation/recommendation statement on Schedule 14D-9 will be filed by ArQule with the SEC. The offer to purchase Shares will only be made
      pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME,
      BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Investors and security holders may obtain a free copy of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such
      requests to the Information Agent for the offer, which will be named in the tender offer statement. Additional copies of the tender offer materials may be obtained at no charge by contacting Merck at 2000 Galloping Hill Road, Kenilworth, N.J., 07033
      or by phoning (908) 423-1000. In addition, Merck and ArQule file annual, quarterly and current reports and other information with the SEC. Merck&#8217;s and ArQule&#8217;s filings with the SEC are also available to the public from commercial document-retrieval
      services and at the SEC&#8217;s website at www.sec.gov.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 5. Interest in Securities of ArQule</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">(a), (b). Other than those Subject Shares that may be deemed to be beneficially owned in connection with the Support Agreement, the Reporting Persons have not acquired and, for the purposes of
      Rule 13d-4 promulgated under the Exchange Act, do not beneficially own any Shares. As a result of the Support Agreements, the Reporting Persons may be deemed to have the power to vote against certain matters set forth in Item 4 above and cause the
      disposition of up to an aggregate of 17,481,903 Shares, and thus, for the purpose of Rule 13d-3 promulgated under the Exchange Act, the Reporting Persons may each be deemed to be the beneficial owner of an aggregate of 17,481,903 Shares. The Subject
      Shares that may be deemed to be beneficially owned by the Reporting Persons constitute approximately 12.6% of the Shares issued and outstanding as of the close of business on December 5, 2019, as represented by ArQule in the Merger Agreement. The
      Reporting Persons are not entitled to any rights as stockholders of ArQule as to the Subject Shares, except as otherwise expressly provided in the Support Agreements. This Schedule 13D shall not be construed as an admission by the Reporting Persons
      that the Reporting Persons are, for the purposes of Section 13(d) of the Exchange Act, the beneficial owners of the Subject Shares. Except as set forth herein, none of the Reporting Persons nor, to the knowledge of the Reporting Persons, any of the
      persons named in Schedule A hereto beneficially own any Shares.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">(c). Except for the Merger Agreement and the Support Agreement, to the knowledge of the Reporting Persons, no transactions in the class of securities reported have been effected during the past
      60 days by any person named in Schedule A or Item 5(a).</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">(d). To the knowledge of the Reporting Persons, based on representations made by the Stockholders in the Support Agreements, other than the Stockholders, no other person has the right to
      receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities of ArQule reported herein.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">(e). Not applicable.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of ArQule</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Except for the Merger Agreement, the Support Agreements and the Non-Disclosure Agreement, to the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or
      relationships (legal or otherwise), including, but not limited to, transfer or voting of any of the securities, finder&#8217;s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the
      giving or withholding of proxies, among the persons named in Item 2 or between such persons and any other person, with respect to any securities of Issuer, including any securities pledged or otherwise subject to a contingency the occurrence of which
      would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 7. Material to Be Filed as Exhibits</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4957ffeba1344f3284fd3b8c0c7f7c3e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5.62%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/1019695/000110465919070788/tm1924665d1_ex2-1.htm">2.1</a></div>
          </td>
          <td style="width: 94.38%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Agreement and Plan of Merger, dated as of December 6, 2019, among ArQule, Inc., Merck Sharp &amp; Dohme Corp. and Argon Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the
              Current Report on Form 8-K filed by ArQule, Inc. with the SEC on December 9, 2019).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5.62%; vertical-align: top;">&#160;</td>
          <td style="width: 94.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.62%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/1019695/000110465919070788/tm1924665d1_ex99-1.htm">99.1</a></div>
          </td>
          <td style="width: 94.38%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Form of Tender and Support Agreement, dated as of December 6, 2019, among Merck Sharp &amp; Dohme Corp, Argon Merger Sub, Inc. and certain stockholders of ArQule, Inc. (incorporated by
              reference to Exhibit 99.1 to the Current Report on Form 8-K filed by ArQule, Inc. with the SEC on December 9, 2019).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5.62%; vertical-align: top;">&#160;</td>
          <td style="width: 94.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.62%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;"><a href="nc10006926x1_ex99-2.htm">99.2</a></div>
          </td>
          <td style="width: 94.38%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Amended and Restated Mutual Confidential Disclosure Agreement, effective as of November 25, 2019, between ArQule, Inc. and Merck Sharp &amp; Dohme Corp.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5.62%; vertical-align: top;">&#160;</td>
          <td style="width: 94.38%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.62%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;"><a href="nc10006926x1_ex99-3.htm">99.3</a></div>
          </td>
          <td style="width: 94.38%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Joint Filing Agreement, dated as of December 16, 2019, among Merck &amp; Co., Inc., Merck Sharp &amp; Dohme Corp. and Argon Merger Sub, Inc.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Signature</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman', Times, serif;">After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z708e8a2922c94a049e016e721f6ca00c" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Date: December 16, 2019</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">MERCK &amp; CO. INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 44%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid black;">
            <div style="font-family: 'Times New Roman', Times, serif;">/s/ Robert M. Davis</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Robert M. Davis</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Global Services and Chief Financial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 44%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">MERCK SHARP &amp; DOHME CORP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 44%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid black;">
            <div style="font-family: 'Times New Roman', Times, serif;">/s/ Sunil A. Patel</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Sunil A. Patel</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Senior Vice President, Corporate Development</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 44%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">ARGON MERGER SUB, INC.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid black;">
            <div style="font-family: 'Times New Roman', Times, serif;">/s/ Faye C. Brown</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Faye C. Brown</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Schedule A</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">1.&#160; Merck &amp; Co., Inc.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The name, business address, title, present principal occupation or employment of each of the directors and executive officers of Merck &amp; Co., Inc. are set forth below. If no business
      address is given, the director&#8217;s or executive officer&#8217;s business address is c/o Merck &amp; Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey, 07033.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Unless otherwise indicated below, all of the persons listed below are citizens of the United States of America.</div>
    <div style="font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z63840651bfa94e19ac1bf63fb2740ffa" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Name</div>
          </td>
          <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Position with Merck &amp; Co., Inc.</div>
          </td>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Principal Occupation and Employer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Leslie A. Brun</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Chief Executive Officer and Chairman, Sarr Group, LLC, 435 Devon Park Drive, 700 Building, Wayne, PA 19087</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Thomas R. Cech</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Distinguished Professor of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Mary Ellen Coe</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">President, Google Customer Solutions</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Pamela J. Craig</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Kenneth C. Frazier</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Chairman, President and Chief Executive Officer&#894; Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Chairman, President and Chief Executive Officer&#894; Director, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Thomas H. Glocer</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Founder and Managing Partner, Angelic Ventures LP,&#160;845 3rd Avenue, 4th Floor, New York, NY 10022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Rochelle B. Lazarus</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Chairman Emeritus of Ogilvy &amp; Mather, 636 11th Avenue, New York, NY 10036</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Paul B. Rothman</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Chief Executive Officer, Johns Hopkins Medicine; Dean of the Medical Faculty and Vice President for Medicine, Johns Hopkins University, 725 N. Wolfe Street, Baltimore, MD 21205</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Patricia F. Russo</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Non-executive Chairman, Hewlett Packard Enterprise Company, 6280 America Center Drive, San Jose, CA 95002</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Inge G. Thulin</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Chairman, 3M Company, 3M Center, St. Paul, MN 55144</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Wendell P. Weeks</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Chairman, Chief Executive Officer and President, Corning Incorporated, One Riverfront Plaza, Corning, NY 14831</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Peter C. Wendell</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Managing Director, Sierra Ventures, 1400 Fashion Island Boulevard, Suite 1010, San Mateo, CA 94404</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Sanat Chattopahyay</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and President, Merck Manufacturing Division</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and President, Merck Manufacturing Division, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Frank Clyburn</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Chief Commercial Officer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Chief Commercial Officer, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Robert M. Davis</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Global Services and Chief Financial Officer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Global Services and Chief Financial Officer, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Richard R. Deluca, Jr.</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and President, Merck Animal Health</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and President, Merck Animal Health, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Julie L. Gerberding</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health, Merck &amp; Co., Inc.</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb6425beb81304c55b4de88003a80a2c2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Steven C. Mizell</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Human Resources</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Human Resources, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Michael T. Nally</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Chief Marketing Officer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Chief Marketing Officer, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Roger M. Perlmutter</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and President, Merck Research Laboratories</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and President, Merck Research Laboratories, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Jennifer L. Zachary</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and General Counsel</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President and General Counsel, Merck &amp; Co., Inc.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">2.&#160; Merck Sharp &amp; Dohme Corp.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The name, business address, title, present principal occupation or employment of each of the directors and executive officers of Parent are set forth below. If no business address is given, the
      director&#8217;s or executive officer&#8217;s business address is c/o Merck &amp; Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Unless otherwise indicated below, all of the persons listed below are citizens of the United States of America.</div>
    <div style="font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z345c9ad771234fd2820b1eb3af299c10" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Name</div>
          </td>
          <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Position at Parent</div>
          </td>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Principal Occupation and Employer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Rita Karachum</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director; President</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Senior Vice President Finance &#8211; Global Controller, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Caroline Litchfield</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director; Senior Vice President and Treasurer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Corporate Treasurer and Senior Vice President, Treasury, Tax &amp; Investor Relations, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Timothy G. Dillane</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Juanita Lee</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Michael G. Schwartz</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Geralyn Ritter</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Secretary</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Senior Vice President, Corporate Secretary and Assistant General Counsel, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Faye C. Brown</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Senior Assistant Secretary, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Katie Fedosz</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Jon Filderman</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director; Vice President</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Vice President, Parent</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Salvatore Lombardo</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary, Tax</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary, Tax, Parent</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Jerome Mychalowych</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Senior Vice President, Corporate Tax</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Senior Vice President, Corporate Tax, Parent</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">3.&#160; Argon Merger Sub, Inc.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">The name, business address, title, present principal occupation or employment of each of the directors and executive officers of Merger Sub are set forth below. If no business address is given,
      the director&#8217;s or executive officer&#8217;s business address is c/o Merck &amp; Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033.&#160; Unless otherwise indicated below, all of the persons listed below are citizens of the United States of America.</div>
    <div style="font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zddcb87fbf2974230ac80a10ef8a416ba" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Name</div>
          </td>
          <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Position at Merger Sub</div>
          </td>
          <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Principal Occupation and Employer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Rita Karachum</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director; President</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Senior Vice President Finance &#8211; Global Controller, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Caroline Litchfield</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director; Senior Vice President and Treasurer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Corporate Treasurer and Senior Vice President, Treasury, Tax &amp; Investor Relations, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Timothy G. Dillane</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Juanita Lee</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Faye C. Brown</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Senior Assistant Secretary, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Katie Fedosz</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Michael G. Schwartz</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Treasurer, Merck &amp; Co., Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Jon Filderman</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Director; Secretary</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Vice President, Parent</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>2
<FILENAME>nc10006926x1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 6.5.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> </u>
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.2<u><br>
      </u></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>AMENDED AND RESTATED MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</u></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt; font-family: 'Times New Roman', Times, serif;">This Amended and Restated Mutual Confidential Disclosure Agreement (this "<font style="font-weight: bold;">Agreement</font>"), effective as of the date of
      last signature below (the "<font style="font-weight: bold;">Effective Date</font>"), is entered into by and between Merck Sharp &amp; Dohme Corp., having an address of 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (hereinafter referred to as
      "<font style="font-weight: bold;">Merck</font>") and ArQule, Inc., having an address of One Wall Street, Burlington, Massachusetts 01803 (hereinafter referred to as "<font style="font-weight: bold;">ArQule</font>") (each a "<font style="font-weight: bold;">Party</font>" and collectively, the "<font style="font-weight: bold;">Parties</font>") and sets forth the terms and conditions under which the Parties will exchange certain proprietary and confidential information/data related to ArQule's
      business, and its clinical pipeline of orally bioavailable product candidates, including BTK inhibitor ARQ 531 (the <font style="font-weight: bold;">"Lead Compound"</font>) and Merck's interest therein (hereinafter collectively referred to as "<font style="font-weight: bold;">Subject Matter</font>").</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">All proprietary and non-public
        information/data respecting the Subject Matter that is disclosed to one Party (the "<font style="font-weight: bold;">Receiving Party</font>") or its Representatives by or on behalf of the other Party, and, in the case of Merck, by or on behalf of
        Merck's Affiliates, (the "<font style="font-weight: bold;">Disclosing Party</font>") whether in oral, written, graphic or electronic form, shall be considered "<font style="font-weight: bold;">Confidential Information</font>", including, but not
        limited to, information regarding data, inventions, know-how, ideas, procedures, formulations, compounds, biologics, designs, methods, techniques, financial projections and/or terms, software, developmental or experimental work, clinical or other
        programs, and plans for research and development of a Party. Confidential Information of the Disclosing Party, in whole or in part, contained or incorporated in any copies, summaries, notes, reports, translations, analyses and/or studies, whether
        written or recorded in electronic or other format and on whatever media, shall also constitute Confidential Information of the Disclosing Party. For purposes of this Agreement, "<font style="font-weight: bold;">Affiliate</font>" means an entity at
        least 50% owned by, under common ownership with, or which owns at least 50% of, Merck.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Receiving Party shall maintain the
        secrecy of all Confidential Information disclosed to it by the Disclosing Party hereunder and shall use such Confidential Information only for the purpose of evaluating its interest in a potential (i) arrangement with the Disclosing Party for
        research, development and/or commercialization regarding the Lead Compound and any backups thereto and/or (ii) negotiated business combination transaction or negotiated acquisition of ArQule (and any applicable subsidiaries thereof) by Merck or an
        Affiliate thereof (the "<font style="font-weight: bold;">Purpose</font>").</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt; font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Receiving Party shall not disclose any Confidential Information of the Disclosing Party to any third party, except to its officers, employees, agents, advisors and consultants (collectively "<font style="font-weight: bold;">Representatives</font>")
        who have a need to know such Confidential Information for the Purpose and who are bound to maintain the confidentiality of the Confidential Information by written obligations of confidentiality and non-use at least as restrictive as those contained
        in this Agreement. Merck may also disclose Confidential Information of ArQule, on a need to know basis for the Purpose, to Merck's Affiliates who shall be under the obligations of confidentiality and non-use set forth herein. Each Party shall (i)
        advise its Representatives of the proprietary nature of the Confidential Information and the terms and conditions of this Agreement requiring that the confidentiality of any such information be maintained and (ii) use all reasonable
      safeguards to prevent unauthorized use by such Representatives. Each Party shall be responsible for any non-compliance with, or breach of, this Agreement by any of its Representatives, and in the case of Merck, its Affiliates, to which such Party has
      disclosed any Confidential Discussions (as defined below) and/or the other Party's Confidential Information.</div>
    <div style="text-align: justify; margin-left: 6pt; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div style="text-align: justify; margin-left: 6pt; font-family: 'Times New Roman', Times, serif;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb4e7c966a30a4b849538babe565cf338" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div><img src="nc10006926x1_ex99-2img01.jpg" height="48" width="126"></div>
            </td>
            <td style="width: 34%; vertical-align: middle; text-align: center;">
              <div style="font-family: 'Times New Roman',Times,serif;">Page 1 of 6<br>
              </div>
            </td>
            <td style="width: 33%; vertical-align: middle; text-align: center;">
              <div style="font-family: 'Times New Roman',Times,serif;">LKR159213</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The obligations of confidentiality and
        non-use shall not apply to Confidential Information that the Receiving Party can demonstrate by contemporaneous, written or electronic documentation:</font></div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z985ab51fcffa4e41a49685195257f783" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 51pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">a)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif;">is in the public domain by use and/or publication at the time of its receipt from the Disclosing Party or thereafter enters into the public domain through no breach of this
                  Agreement by the Receiving Party or its Representatives, and in the case of Merck, its Affiliates; or</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z14a0efcab25c4e1f9666311d5df7bbe5" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 51pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">b)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif;">was already in its or its Representative's possession prior to receipt from the Disclosing Party or is independently developed without use of, or reliance on, Confidential
                  Information received from the Disclosing Party; or</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3fc2e5a5b27b4970b7c771b868195dac" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 51pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">c)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif;">is properly obtained by the Receiving Party or its Representative's from a third party that has a valid right to disclose such Confidential Information and does not have a
                  confidentiality obligation to the Disclosing Party.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">In the event a Receiving Party is required
        to disclose any Confidential Information received under this Agreement in order to comply with any law, regulation or valid court order, such Receiving Party may disclose such Confidential Information only to the extent necessary for such
        compliance; <font style="font-style: italic;">provided, however</font>, that such Receiving Party shall give the other Party reasonable advance written notice of the required disclosure, to the extent permitted by law, to provide such other Party
        with the opportunity to seek confidential treatment of any Confidential Information to be disclosed and/or to obtain a protective order narrowing the scope of disclosure and shall reasonably cooperate with such other Party's efforts to seek
        confidential treatment of any Confidential Information to be disclosed and/or to obtain a protective order narrowing the scope of disclosure. Confidential Information that is disclosed pursuant to such required disclosure shall remain otherwise
        subject to the confidentiality and non-use provisions set forth herein.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">For a period of one (1) year following the
        Effective Date, Merck shall not, and shall cause its Affiliates not to, directly or indirectly, solicit or cause to be solicited for employment or employ, hire or contract with (as an employee or independent contractor) any Specified Employee (as
        defined below) or otherwise induce or attempt to induce any Specified Employee to terminate or otherwise cease his or her employment with ArQule or any of its subsidiaries; provided, however, the foregoing provision will not apply with respect to
        (a) any general solicitation which is not directed specifically to officers or employees of ArQule and its subsidiaries, or (b) any Specified Employee who has been terminated by ArQule or its subsidiaries prior to commencement of employment
        discussions between Merck or its Affiliates and such Specified Employee. A "<font style="font-weight: bold;">Specified Employee</font>" means those employees listed on Exhibit A.</font></div>
    <div>
      <div style="text-align: justify; margin-left: 6pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 6pt; font-family: 'Times New Roman', Times, serif;">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 33%; vertical-align: top;">
                <div><img src="nc10006926x1_ex99-2img01.jpg" height="48" width="126"></div>
              </td>
              <td style="width: 34%; vertical-align: middle; text-align: center;">
                <div style="font-family: 'Times New Roman',Times,serif;">Page 2 of 6<br>
                </div>
              </td>
              <td style="width: 33%; vertical-align: middle; text-align: center;">
                <div style="font-family: 'Times New Roman',Times,serif;">LKR159213</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageFooter"></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Merck agrees that until the one (1)-year
        anniversary of the Effective Date (the "<font style="font-weight: bold;">Standstill Expiration Date</font>"), unless specifically invited by the Board of Directors of ArQule (the "<font style="font-weight: bold;">Board</font>"), neither Merck nor
        any of its Affiliates or Representatives acting on behalf of Merck or its Affiliates shall (and Merck shall cause its Affiliates and direct its Representatives acting on behalf of Merck or its Affiliates not to), directly or indirectly:</font></div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8d775e30c360433aa3f23c7ab206e809" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 51pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">a)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif;">effect or propose, or announce any intention to effect or knowingly facilitate or knowingly encourage any other person to effect or propose or announce any intention to effect: (i)
                  the acquisition of record or beneficial ownership of any voting securities of ArQule or any rights to acquire such voting securities; (ii) any merger, consolidation, or business combination with ArQule; (iii) any recapitalization,
                  restructuring, liquidation, dissolution or other similar extraordinary transaction with respect to ArQule; or (iv) any "solicitation" of "proxies" (as such terms are used in Regulation 14A of the Exchange Act) or consents to vote (whether
                  or not related to the election or removal of directors) with respect to any voting securities of ArQule, or the initiation, proposal, encouragement or solicitation of stockholders of ArQule for the approval of any stockholder proposals
                  with respect to ArQule, or the solicitation, advisement or influence of any person with respect to the voting of any voting securities of ArQule;</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd168391823a147a7afed09cce9f710df" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 51pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">b)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif;">form, join or in any way participate in a "group" as defined in Section 13(d)(3) or Section 14(d)(2) of the Exchange Act with respect to any voting securities of ArQule or otherwise
                  in connection with any of the foregoing;</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9a8e3d647e354e13a3cf373252bcff2f" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 51pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">c)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif;">(i) call or seek to call any meeting of stockholders of ArQule, including by written consent, or provide to any third party a proxy, consent or requisition to call any meeting of
                  stockholders of ArQule; (ii) seek representation on the Board; or (iii) seek the removal of any member of the Board or management of ArQule; or</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5d282e1c8e794e2d8b086a5e47c12518" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 51pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif;">d)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif;">publicly disclose any intention, plan or arrangement, whether written or oral, inconsistent with the foregoing;</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt; font-family: 'Times New Roman', Times, serif;">provided, however, that notwithstanding the foregoing, Merck (and its Affiliates and Representatives acting on behalf of Merck) shall not be restricted
      from (i) making a private, confidential proposal for a transaction involving ArQule or any of its subsidiaries solely to the senior management or the Board that would not reasonably be expected to require Merck or ArQule to make any public disclosure
      with respect thereto, (ii) making any offer or entering into any commercial transaction with respect to, or otherwise consummating, any commercial transaction in the ordinary course of business, and wholly unrelated to a business combination
      transaction or acquisition of ArQule or any of its subsidiaries, (iii) making any acquisition of a company or business unit thereof that causes Merck or its Affiliates to "beneficially own" (as such term is used in Rule 13d-3 of the Exchange Act)
      securities of ArQule or any of its subsidiaries (or any derivative securities) so long as the purchase of such securities was not made on behalf of Merck or its Affiliates and the acquisition of such company or business unit was not made for the
      purpose of indirectly acquiring such securities.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt; font-family: 'Times New Roman', Times, serif;">Merck will cease to be bound by the provisions of, and Merck's restriction on the use of the Confidential Information will not prohibit the actions in,
      clauses (a) through (d) above, upon the earliest to occur of the following: (i) the Standstill Expiration Date; (ii) the Board approves, or ArQule or its subsidiaries enters into, a transaction with any Person that would result in such Person
      beneficially owning (A) more than 50% of ArQule's outstanding voting securities, (B) securities convertible into or exercisable for more than 50% of ArQule's outstanding voting securities or (C) all or substantially all of the assets of ArQule and
      its subsidiaries; or (iii) any person or entity, including any persons or entities acting in concert, shall have commenced a tender offer or exchange offer for more than 50% of ArQule's outstanding voting securities and the Board shall have either
      recommended that ArQule's stockholders tender or exchange in such offer or failed to recommend that ArQule's stockholders reject such offer within ten (10) business days following the commencement of any such offer.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Unless sooner terminated, for or without
        cause, by written notice from one Party to the other sent to the addresses set forth above, this Agreement shall expire on the first (1st) anniversary of the Effective Date. Notwithstanding any expiration or termination of this Agreement, the
        Receiving Party's obligations of confidentiality and non-use concerning Confidential Information of the other Party shall survive until the seventh (7th) anniversary of the expiration or earlier termination of this Agreement.</font></div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-align: justify; margin-left: 6pt;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div><img src="nc10006926x1_ex99-2img01.jpg" height="48" width="126"></div>
            </td>
            <td style="width: 34%; vertical-align: middle; text-align: center;">
              <div style="font-family: 'Times New Roman',Times,serif;">Page 3 of 6<br>
              </div>
            </td>
            <td style="width: 33%; vertical-align: middle; text-align: center;">
              <div style="font-family: 'Times New Roman',Times,serif;">LKR159213</div>
            </td>
          </tr>

      </table>
      <font style="font-family: 'Times New Roman', Times, serif;"> </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Upon the earlier of written request of the
        Disclosing Party or termination or expiration of this Agreement, all Confidential Information received by the Receiving Party from or on behalf of the Disclosing Party shall be promptly returned to the Disclosing Party or destroyed, as determined
        by the Receiving Party, <font style="font-style: italic;">provided, however </font>that the Receiving Party may retain one (1) copy of such Confidential Information in its confidential files, solely for purposes of exercising the Receiving
        Party's rights hereunder, satisfying its obligations hereunder or complying with any legal proceeding or requirement with respect thereto and <font style="font-style: italic;">further, provided</font>, that the Receiving Party shall not be
        required to erase electronic files created in the ordinary course of business during automatic system back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and
        information so long as such electronic files are (i) maintained only on centralized storage servers (and not on personal computers or devices), (ii) not accessible by any of its personnel (other than its information technology specialists), and
        (iii) are not otherwise accessed subsequently except with the written consent of the Disclosing Party or as required by law or legal process. Such retained copies of Confidential Information shall remain subject to the confidentiality and non-use
        obligations herein.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">All Confidential Information of a
        Disclosing Party that is disclosed hereunder shall remain the property of that Party. No patent or ownership right or license is granted by this Agreement, except for the Receiving Party's right to use the Confidential Information solely for the
        Purpose, and the parties acknowledge that the disclosure of Confidential Information hereunder does not result in any obligation of the Disclosing Party to grant the Receiving Party further rights in or to such Confidential Information or for the
        Parties to enter into further negotiations or any agreement with each other in relation to the Subject Matter.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Disclosing Party makes no
        representation or warranty, express or implied, as to the accuracy or completeness of the Confidential Information, and shall have no liability as to the accuracy or completeness of the Confidential Information on any basis (including, without
        limitation, in contract, tort, under applicable securities laws or otherwise). The Receiving Party will not make any claims whatsoever against the Disclosing Party for any omissions or errors included in the Confidential Information. The Disclosing
        Party shall have no liability or responsibility for any decisions made by the Receiving Party in reliance on any Confidential Information disclosed under this Agreement. The Disclosing Party expressly disclaims any express or implied duty to
        update, supplement or correct any Confidential Information disclosed hereunder.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">The Parties acknowledge that a material
        breach of this Agreement by the Receiving Party may cause irreparable harm to the Disclosing Party and that no remedy at law may adequately compensate the Disclosing Party for such harm. The Disclosing Party shall have the right to seek injunctive
        relief or other equitable relief without prejudice to any other rights or remedies that the Disclosing Party may have for the material breach of this Agreement.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Except in order to comply with any law,
        regulation or valid court order in accordance with the provisions of paragraph 5 applicable to Confidential Information, no disclosure of the existence, or the terms, of this Agreement or the fact that discussions may be taking place between the
        Parties regarding the Subject Matter or the Purpose or the terms or status thereof ("<font style="font-weight: bold;">Confidential Discussions</font>") may be made by either Party except to its Representatives, and also in the case of Merck to its
        Affiliates, who have a need to know such Confidential Discussions for the Purpose, and who are bound to maintain the confidentiality of such Confidential Discussions by written obligations of confidentiality and non-use at least as restrictive as
        those contained in this Agreement. Further, no Party shall use the name, trademark, trade name, or logo of the other Party, its affiliates, or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this
        Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by law.</font></div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-align: justify; margin-left: 6pt;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div><img src="nc10006926x1_ex99-2img01.jpg" height="48" width="126"></div>
            </td>
            <td style="width: 34%; vertical-align: middle; text-align: center;">
              <div style="font-family: 'Times New Roman',Times,serif;">Page 4 of 6<br>
              </div>
            </td>
            <td style="width: 33%; vertical-align: middle; text-align: center;">
              <div style="font-family: 'Times New Roman',Times,serif;">LKR159213</div>
            </td>
          </tr>

      </table>
      <font style="font-family: 'Times New Roman', Times, serif;"> </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageFooter"></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">Except as provided in this paragraph,
        this Agreement may not be assigned by either Party without the prior written consent of the other Party, except that (i) either Party may assign this Agreement to any successor in interest to all or substantially all of the business or assets of
        any Party, provided that such assignee agrees in writing to be responsible for all obligations of the assigning Party and (ii) Merck may assign this Agreement to any of its Affiliates provided that Merck shall remain responsible for its obligations
        hereunder. This Agreement shall inure to the benefit of and be binding on the Parties and their respective successors and permitted assigns. No failure or delay on the part of either Party in exercising any right under this Agreement shall operate
        as a waiver of, or impair, any such right. No single or partial exercise of any such right shall preclude any other or further exercise thereof or the exercise of any other right. No waiver of any such right shall have effect unless given in a
        signed, written document. No waiver of any right shall be deemed a waiver of any other right under this Agreement. Any assignment other than as permitted by this paragraph shall be null and void.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">15.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">This Agreement represents the entire
        understanding between the Parties, and hereby supersedes any prior understandings, whether oral or written, between the Parties with respect to the subject matter hereof, including, but not limited to, that certain Mutual Confidential Disclosure
        Agreement between the Parties effective as of August 21, 2019. This Agreement may not be modified, amended, waived or otherwise changed, in whole or in part, except in a writing that is signed by the authorized representatives of the Parties. If
        any portion of this Agreement or the application thereof to either Party is held by a court of competent jurisdiction to be invalid, illegal, non-binding or unenforceable in any respect, this Agreement shall be construed as if such invalid,
        illegal, non-binding or unenforceable provision had never been contained herein and the remaining portion hereof or applications to a Party shall remain in full force and effect.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">16.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">This Agreement shall be governed by and
        construed and enforced according to the laws of the State of New York, United States of America, without regard to its principles of conflicts of laws.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 6pt;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">17.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', Times, serif;">This Agreement may be signed in any
        number of counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. Signatures to this Agreement may be provided by facsimile transmission or PDF file, which shall be deemed to be
        original signatures.</font></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[<font style="font-style: italic;">Signature Page Follows</font>]</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div><img src="nc10006926x1_ex99-2img01.jpg" height="48" width="126"></div>
            </td>
            <td style="width: 34%; vertical-align: middle; text-align: center;">
              <div style="font-family: 'Times New Roman',Times,serif;">Page 5 of 6<br>
              </div>
            </td>
            <td style="width: 33%; vertical-align: middle; text-align: center;">
              <div style="font-family: 'Times New Roman',Times,serif;">LKR159213</div>
            </td>
          </tr>

      </table>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      <div id="DSPFPageHeader"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z1f962852dedc47b1acbf2d862b3285d7" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Merck Sharp &amp; Dohme Corp.</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ArQule, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman', Times, serif;">By</div>
            </td>
            <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman', Times, serif;">/s/ Michael Flaschen</div>
            </td>
            <td style="width: 4%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman', Times, serif;">By</div>
            </td>
            <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman', Times, serif;">/s/ Peter Lawrence</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Michael Flaschen</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Peter Lawrence</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Name</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Name</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Head of HQ Transactions</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">President &amp; COO</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Title</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Title</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Nov. 25, 2019</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">11-23-2019</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Date</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Date</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 33%; vertical-align: top;">
                <div><img src="nc10006926x1_ex99-2img01.jpg" height="48" width="126"></div>
              </td>
              <td style="width: 34%; vertical-align: middle; text-align: center;">
                <div style="font-family: 'Times New Roman',Times,serif;">Page 6 of 6<br>
                </div>
              </td>
              <td style="width: 33%; vertical-align: middle; text-align: center;">
                <div style="font-family: 'Times New Roman',Times,serif;">LKR159213</div>
              </td>
            </tr>

        </table>
        <div>
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>3
<FILENAME>nc10006926x1_ex99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 6.5.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.3</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Joint Filing Agreement</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule
      13D (including amendments thereto) with respect to the common stock, par value $0.01 per share, of ArQule, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.&#160; In evidence
      thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of the date set forth below.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za0a7e0a44aa842c3acd876bb84e54dea" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Date: December 16, 2019</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">MERCK &amp; CO. INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 44%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid black;">
            <div style="font-family: 'Times New Roman', Times, serif;">/s/ Robert M. Davis</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Robert M. Davis</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Executive Vice President, Global Services and Chief Financial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 44%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">MERCK SHARP &amp; DOHME CORP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 44%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid black;">
            <div style="font-family: 'Times New Roman', Times, serif;">/s/ Sunil A. Patel</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Sunil A. Patel</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Senior Vice President, Corporate Development</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 44%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">ARGON MERGER SUB, INC.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top; border-bottom: 2px solid black;">
            <div style="font-family: 'Times New Roman', Times, serif;">/s/ Faye C. Brown</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Faye C. Brown</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Assistant Secretary</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>nc10006926x1_ex99-2img01.jpg
<TEXT>
begin 644 nc10006926x1_ex99-2img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q 'X# 2(  A$! Q$!_\0
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MXI/AVQTVQ2XMV5$/GL0"6(;EP#D;1UQ7Z)0K0KTXU8;25S@::=F>IT5YC?\
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MV+N&&QSBO=X:^M4J#P^(@XVU5UT?3[_S,<1RM\T64;C0])N[V&\N=,LYKJ'
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0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
